Entries by Michael Kuhrt

Nouscom: New hire for operations

Swiss oncology expert Nouscom has appointed Marina Udier Blagovic as its Chief Operating Officer. The position has been newly created to drive all aspects of business operations and business development.

Crescendo Biologics: Finance pro

Cambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs. 

Nordic Nanovector: New on board

Oslo-based Nordic Nanovector has elected Joanna Horobin to its board as Non-executive Board Director. She replaces Renee Tannenbaum who stepped down from the board for personal reasons.

Curevac: In command of finance

German mRNA company Curevac AG has appointed Pierre Kemula as Chief Financial Officer. Kemula joins Curevac from medtech firm Pixium Vision, where he was also responsible for financial activities.

Laurels for stem cell groundbreaker

The Royal Swedish Academy of Sciences has awarded the Tobias Prize 2016 to stem cell researcher David Bryder of Lund University for his groundbreaking hematopoietic stem cell discoveries.

Why new approaches that target sepsis need support

With globally at least 30 million of cases per year, sepsis is a major health threat for which a specific adjunctive sepsis therapy beyond antimicrobial treatment, surgical source control and supportive intensive care measure is still missing.

In the Brexshit

Well, those bloody idiots in the UK managed to do it talk themselves from decades of hysteria about straight bananas (entirely fabricated by one B Johnson during his time as a journalist in Brussels) into actually voting to leave.

Prothena: Filling in for a friend

Dublin-based protein immunotherapy developer Prothena has appointed Gene Kinney as its new President and Chief Executive Officer. Kinney has also been appointed to Prothena’s Board of Directors.

Immunicum: Doctor takes the lead

Swedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma.

TxCell: Board ahoy

Immunotherapy maker TxCell SA has appointed gene therapy expert Olivier Danos to its newly founded Scientific Advisory Board. Danos serves as Senior Vice President of Cell and Gene Therapy at Biogen and has led Biogen’s gene therapy research group for the last two years. Previously, Danos served as Senior VP Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals.